Pharmacokinetic effect of disease severity and use of extracorporeal membrane oxygenation in critically ill Asian patients receiving vancomycin

被引:0
|
作者
Avachat, Charul [1 ]
Hung, Pi-lien [2 ,3 ]
Birnbaum, Angela K. [1 ]
Healy, Daniel P. [4 ]
Sherwin, Catherine M. [1 ,5 ,6 ,7 ]
Lin, Alex C. [4 ]
机构
[1] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Kaohsiung Vet Gen Hosp, Dept Pharm, Div Clin Pharm, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Sch Pharm, Coll Pharm, Kaohsiung, Taiwan
[4] Univ Cincinnati, James L Winkle Coll Pharm, Cincinnati, OH USA
[5] Univ Western Australia, UWA Med Sch, Internal Med, Perth, WA, Australia
[6] Differentia Biotech Ltd, San Francisco, CA 94080 USA
[7] Wright State Univ, Boonshoft Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA
关键词
vancomycin; pharmacokinetics; extracorporeal membrane oxygenation (ECMO); critically ill patients; methicillin-resistant Staphylococcus aureus (MRSA); AUGMENTED RENAL CLEARANCE; POPULATION PHARMACOKINETICS; INTERMITTENT HEMODIALYSIS; FEBRILE NEUTROPENIA; PEDIATRIC-PATIENTS; CHILDREN;
D O I
10.3389/fphar.2025.1506793
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose Vancomycin is an essential antibiotic for the treatment of severe gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA). In critically ill patients, particularly children, attaining the appropriate dosage is crucial to avert drug resistance and ensure therapeutic efficacy. This study sought to investigate the pharmacokinetics of vancomycin in critically ill Asian pediatric patients and evaluate the influence of extracorporeal membrane oxygenation (ECMO) and disease severity on vancomycin clearance.Methods This retrospective analysis examined data from 90 critically ill Asian patients residing in Kaohsiung, Taiwan, encompassing 263 data points gathered over 2 years. A one-compartment pharmacokinetic model with first-order elimination was constructed using nonlinear mixed-effects modeling to assess the impact of ECMO and infection severity on vancomycin clearance.Results The pharmacokinetics of vancomycin were markedly affected by ECMO and the severity of the illness. Patients using ECMO demonstrated a 56% decrease in vancomycin clearance relative to non-ECMO patients. Furthermore, patients with milder infections (e.g., cellulitis, surgical prophylaxis, neutropenic fever) had a 39% decrease in vancomycin clearance relative to those with more severe infections (e.g., pneumonia, bacteremia, osteomyelitis, meningitis, deep tissue infection).Conclusion The study demonstrates that ECMO and infection severity are major factors influencing vancomycin clearance in critically unwell pediatric patients. The significant decrease in clearance linked to ECMO and reduced infection severity underscores the necessity for meticulous therapeutic drug monitoring and tailored dosing strategies to enhance vancomycin treatment in this at-risk population. The findings highlight the significant interindividual diversity in vancomycin pharmacokinetics in critically unwell pediatric patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation
    An, Sook Hee
    Lee, Eun Mi
    Kim, Jae Yeon
    Gwak, Hye Sun
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (E1) : E25 - E29
  • [2] Antimicrobial Exposures in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation
    Shekel, Kiran
    Abdul-Aziz, Mohd H.
    Cheng, Vesa
    Burrows, Fay
    Buscher, Hergen
    Cho, Young-Jae
    Corley, Amanda
    Diehl, Arne
    Gilder, Eileen
    Jakob, Stephan M.
    Kim, Hyung-Sook
    Levkovich, Bianca J.
    Lim, Sung Yoon
    McGuinness, Shay
    Parke, Rachael
    Pellegrino, Vincent
    Que, Yok-Ai
    Reynolds, Claire
    Rudham, Sam
    Wallis, Steven C.
    Welch, Susan A.
    Zacharias, David
    Fraser, John F.
    Roberts, Jason A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207 (06) : 704 - 720
  • [3] Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study)
    Cheng, Vesa
    Abdul-Aziz, Mohd H.
    Burrows, Fay
    Buscher, Hergen
    Cho, Young-Jae
    Corley, Amanda
    Diehl, Arne
    Gilder, Eileen
    Jakob, Stephan M.
    Kim, Hyung-Sook
    Levkovich, Bianca J.
    Lim, Sung Yoon
    McGuinness, Shay
    Parke, Rachael
    Pellegrino, Vincent
    Que, Yok-Ai
    Reynolds, Claire
    Rudham, Sam
    Wallis, Steven C.
    Welch, Susan A.
    Zacharias, David
    Fraser, John F.
    Shekar, Kiran
    Roberts, Jason A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
  • [4] Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation
    Seungwon Yang
    Hayeon Noh
    Jongsung Hahn
    Byung Hak Jin
    Kyoung Lok Min
    Soo Kyung Bae
    Jiseon Kim
    Min Soo Park
    Taegon Hong
    Jin Wi
    Min Jung Chang
    Scientific Reports, 7
  • [5] Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation
    Zhang, Li-Chen
    Li, Qiu-Yue
    Zhang, Yu-Qiu
    Shan, Ti-Chao
    Li, Yuan
    Li, Yi-Hui
    Han, Hui
    Qin, Wei-Dong
    Guo, Hai-Peng
    Zhao, Wei
    Tang, Bo-Hao
    Chen, Xiao-Mei
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (07) : 1697 - 1705
  • [6] Population pharmacokinetics of remifentanil in critically ill patients receiving extracorporeal membrane oxygenation
    Yang, Seungwon
    Noh, Hayeon
    Hahn, Jongsung
    Jin, Byung Hak
    Min, Kyoung Lok
    Bae, Soo Kyung
    Kim, Jiseon
    Park, Min Soo
    Hong, Taegon
    Wi, Jin
    Chang, Min Jung
    SCIENTIFIC REPORTS, 2017, 7
  • [7] Renal Replacement Therapy in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation
    Askenazi, David J.
    Selewski, David T.
    Paden, Matthew L.
    Cooper, David S.
    Bridges, Brian C.
    Zappitelli, Michael
    Fleming, Geoffrey M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 7 (08): : 1328 - 1336
  • [8] Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation
    Amaker, RD
    DiPiro, JT
    Bhatia, J
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) : 1139 - 1142
  • [9] A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy
    Moore, J. N.
    Healy, J. R.
    Thoma, B. N.
    Peahota, M. M.
    Ahamadi, M.
    Schmidt, L.
    Cavarocchi, N. C.
    Kraft, W. K.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2016, 5 (09): : 495 - 502
  • [10] A systematic review on pharmacokinetic changes in critically ill patients: role of extracorporeal membrane oxygenation
    Mousavi, S.
    Levcovich, B.
    Mojtahedzadeh, M.
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 19 (05): : 312 - 321